AEGiS-14IAC: Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions (TI) in chronically HIV-1 infected patients.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions (TI) in chronically HIV-1 infected patients.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9016)

Papasavvas E, Grant R, Jun-wei Sun, Mackiewicz A, Pistilli M, Kostman J, Mounzer K, Montaner LJ
Wistar Institute, Philadelphia, United States

BACKGROUND: The effect of TIs on the evolution and persistence of drug-resistant viruses in chronically HIV-1 infected suppressed patients is undetermined.

METHODS: The emergence of viral resistance to ART was monitored in 11 suppressed chronically HIV-1 infected patients (mean follow-up=326 days) undergoing from 1 up to 4 sequential TIs, by genotyping virus for known mutations in the protease and RT gene (a total of 25 TIs). Resistance assays were performed at the first viral rebound > 100 copies/ml.

RESULTS: All subjects achieved re-suppression of HIV-1 under the same ART, regardless of the number of TIs. 3/11 - who had up to 3 sequential TIs - showed no development of resistance. In the remaining 8, 7 mutations associated with viral resistance were detected during the 1st TI (pre-existence of these mutations is unknown). Three of these mutations were persistent (L63P, I64V, K70R) in 7 of these 8 subjects. However, intermittent presence or loss of 6 mutations (M36I, I64V, L63P, M184V, N88N/D, L90M) was found in 3/8 patients following extended TIs, treatment re-initiation and/or during subsequent TIs. Interestingly, 2 subjects showed evidence of evolution of a mutation against 3TC (M184V) or d4T (K219E) not present during the 1st TI, which subsequently disappeared following therapy re-initiation or during next TIs.

CONCLUSIONS: Detection of drug-resistance during treatment interruption does not predict failure to re-suppress after ART re-initiation nor persistence of a resistant viral population during interruptions or subsequent TIs.

Keywords: AEGIS, HIV-1, HIV Protease, Mutation, Lamivudine, HIV-1 Reverse Transcriptase, Antiretroviral Therapy, Highly Active, Proteins, Genotype, Human, therapy, genetics, drug therapyKWDaegis,hiv-1,hivprotease,mutation,lamivudine,hiv-1reversetranscriptase,antiretroviraltherapy,highlyactive,proteins,genotype,human,therapy,genetics,drugtherapy

020707
LbPeB9016

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.